SPI-1005 for the Treatment of Patients With Meniere's Disease

NCT03325790 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Meniere's Disease

Interventions

DRUG: 200mg SPI-1005 BID
DRUG: 400mg SPI-1005 BID
OTHER: Placebo

Sponsor

Sound Pharmaceuticals, Incorporated